Related Experiment Video
Updated: Nov 18, 2025

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 17, 2014
Definitive and Indeterminate Pseudomonas aeruginosa Infection in Adults with Community-acquired Pneumonia: A
Eiichiro Sando1,2,3,4, Motoi Suzuki1, Masayuki Ishida5
1Department of Clinical Medicine and.
Abstract:
Rationale: Pneumonia due to Pseudomonas aeruginosa (PA) is associated with high mortality and requires antipseudomonal treatment. Because PA can colonize the respiratory tract, the diagnosis of pathogenic PA involvement is challenging. Objectives: To determine the prevalence of definitive and indeterminate PA infection in community-acquired pneumonia, to describe the clinical and microbiological profiles, and to estimate the burden of unnecessary antipseudomonal drug prescriptions. Methods: We prospectively enrolled 2,701 patients with community-acquired pneumonia. Using stringent criteria for diagnosing PA pneumonia, we generated the following three groups: 1) definitive PA, 2) indeterminate PA, and 3) non-PA pneumonia. Results: The prevalence of definitive PA pneumonia was 0.9% (n = 25), and that of indeterminate PA pneumonia was 4.9% (n = 131). Considerable clinical differences were observed among the groups. Patients with definitive PA pneumonia were more likely to have a history of tuberculosis and chronic obstructive pulmonary disease/bronchiectasis and had a higher 30-day mortality (28%) than patients with non-PA pneumonia. Patients with indeterminate PA pneumonia were more likely to have comorbidities than patients with non-PA pneumonia. More than half of the patients with indeterminate PA and 25% of the patients with non-PA pneumonia were treated with an antipseudomonal drug. No patients with definitive PA pneumonia had multidrug resistance. Conclusions: In this population, the prevalence of community-acquired pneumonia due to PA was low. The clinical features and 30-day mortality rates of patients with indeterminate PA pneumonia were different from those of patients with definitive PA pneumonia. Most of the prescribed antipseudomonal drugs for patients with community-acquired pneumonia were potentially unnecessary.
Insights
Pseudomonas aeruginosa (PA) pneumonia is rare in community-acquired cases. Many patients receive unnecessary antipseudomonal drugs, highlighting diagnostic challenges and treatment optimization needs.
Area of Science:
- Infectious Diseases
- Pulmonology
- Clinical Microbiology
Background:
- Pneumonia caused by Pseudomonas aeruginosa (PA) has a high mortality rate, necessitating specific antipseudomonal treatment.
- Diagnosing pathogenic PA involvement in pneumonia is difficult due to its potential for respiratory tract colonization.
Purpose of the Study:
- To assess the prevalence of definitive and indeterminate PA infections in community-acquired pneumonia (CAP).
- To characterize the clinical and microbiological profiles of PA pneumonia.
- To quantify the extent of potentially unnecessary antipseudomonal drug prescriptions in CAP.
Main Methods:
- Prospective enrollment of 2,701 patients diagnosed with community-acquired pneumonia.
- Application of stringent criteria to categorize patients into definitive PA, indeterminate PA, and non-PA pneumonia groups.
- Analysis of clinical features, microbiological data, and treatment patterns.
Main Results:
- The prevalence of definitive PA pneumonia was 0.9%, and indeterminate PA pneumonia was 4.9%.
- Patients with definitive PA pneumonia showed higher 30-day mortality (28%) and a greater likelihood of prior tuberculosis and COPD/bronchiectasis.
- Over half of indeterminate PA cases and 25% of non-PA cases received antipseudomonal drugs, with no multidrug resistance observed in definitive PA cases.
Conclusions:
- Community-acquired pneumonia due to Pseudomonas aeruginosa is uncommon.
- Clinical presentations and mortality differ between definitive and indeterminate PA pneumonia, impacting treatment decisions.
- A significant proportion of antipseudomonal antibiotic use in CAP appears to be unnecessary, indicating a need for improved diagnostic strategies and antimicrobial stewardship.
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia II: Pathophysiology
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History

